The multiple sclerosis (MS) therapy market continues to evolve, with each new FDA-approved disease-modifying therapy (DMT) further expanding treatment choices. The newest entrants (e.g., Zeposia,…
Clarivate Epidemiology’s coverage of multiple sclerosis (MS) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key multiple sclerosis patient populations covering 171 countries and…
Until recently, FDA-approved treatments for Alzheimer’s disease (AD) were limited to modestly effective symptomatic agents (e.g., donepezil, memantine), but in 2021, Biogen / Eisai’s Aduhelm (…